SUPN

#1833
Supernus Pharmaceuticals, Inc. - Common Stock
44.0 3 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
44.03
44.03
Jahresspanne
42.45
59.68
Tagesänderung
+0.66%
Monatliche Änderung
-4.76%
6 month change
-19.54%
Jahresänderung
-18.46%
Vorheriger Schlusskurs
43.7 4
Open
44.0 3
Tief
44.0 3
Hoch
44.0 3
Volumen
84
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, 22 February 2022

Full document

Business Context and Reporting Period

This Form 8-K was filed by Supernus Pharmaceuticals, Inc. on February 22, 2022. The filing serves as a current report to announce upcoming financial disclosures and a significant regulatory milestone regarding a new drug application.

Key Financial Metrics

The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It only announces the timing for the release of these figures.

  • Upcoming Disclosure: Preliminary fourth quarter and full year 2021 financial results are expected to be reported after market close on February 28, 2022.
  • Guidance: Full year 2022 financial guidance will be released simultaneously with the 2021 results.

Material Changes and Regulatory Developments

The primary material event reported is a regulatory update regarding the Company's apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations:

  • FDA Review Status: The U.S. Food and Drug Administration (FDA) has classified the New Drug Application (NDA) as a Standard Review.
  • Timeline: A Prescription Drug User Fee Act target action date has been established for early October 2022.
  • Commercial Plan: The Company is preparing for a commercial launch of SPN-830 in the first quarter of 2023, contingent upon timely FDA approval.

Outlook, Risks, and Management Commentary

Management has scheduled a conference call and webcast for February 28, 2022, at 4:30 p.m. E.T. to discuss the preliminary results and guidance. The filing includes extensive forward-looking statements subject to various risks, including:

  • Ability to sustain and increase profitability.
  • Ability to raise sufficient capital to implement corporate strategy.
  • Timing and progress of clinical trials and regulatory approvals for product candidates.
  • Ability to increase prescriptions and net revenue.
  • Intellectual property protection and potential infringement issues.

Investor Verification Checklist

  • Verify the actual Q4 and full-year 2021 financial results and 2022 guidance when released on February 28, 2022.
  • Monitor the FDA review process for SPN-830 to confirm the October 2022 action date is met.
  • Assess the Company's capital position and cash runway in the upcoming earnings release to evaluate funding needs for the 2023 commercial launch.
  • Review the detailed risk factors in the Company's periodic reports (10-K/10-Q) regarding regulatory approval uncertainties.

Nachrichten